Although some studies have found that normal cells are more resistant to TXNRD1-targeted inhibition, there is still insufficient evidence from in vivo and clinical trials, and high levels of ROS may contribute to cancer mutagenesis. This evidence concerns the gene TXNRD1 and cancer.